Mirum Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Value Chain Analysis
This Mirum Value Chain Analysis gives you a clear, company-specific view of how Mirum creates value across support and primary activities. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Support Activities
Firm Infrastructure
Mirum Pharmaceuticals keeps firm infrastructure lean, with finance, legal, quality, regulatory, pharmacovigilance, and investor relations built to support a 2025 rare-disease portfolio of 3 marketed therapies. That matters because rare-disease launches rely more on FDA compliance, safety tracking, and capital discipline than on heavy fixed assets. In 2025, this setup helped Mirum scale global operations while keeping overhead tight and decision-making fast.
Human Resource Management
Mirum Pharmaceuticals depends on hiring people with rare-disease, regulatory, medical affairs, and specialty-commercial experience. Small cross-functional teams help it move development, launch, and post-approval work across 2 marketed therapies. In fiscal 2025, that talent mix mattered because Mirum Pharmaceuticals kept scaling a focused rare-disease model with a lean operating structure.
Technology Development
Mirum Pharmaceuticals centers technology development on maralixibat, the oral IBAT inhibitor approved for Alagille syndrome and progressive familial intrahepatic cholestasis, and keeps extending evidence across cholestatic liver diseases. In 2025, this kind of lifecycle work mattered more because Mirum was defending a narrow specialty market with only a few core assets, so every new label, study, and real-world dataset can widen use. The strategy is simple: more clinical proof means stronger payer access and more runway for maralixibat-based growth.
Procurement
Mirum's procurement focuses on qualifying contract manufacturers, API suppliers, CROs, packaging vendors, and specialty service providers. With a small portfolio, Mirum cares more about supplier reliability, batch quality, and cost control than scale, so each vendor must meet tight technical and compliance checks. In a business where one delayed lot can affect launch timing and cash use, procurement has a direct impact on margin and supply continuity.
Mirum Pharmaceuticals Keeps a Lean 2025 Backbone Behind 3 Marketed Therapies
Mirum Pharmaceuticals runs a lean support base in 2025: finance, legal, quality, regulatory, pharmacovigilance, and IR back 3 marketed therapies. Its small, rare-disease team keeps FDA compliance, safety tracking, and supplier control tight while scaling global launches. That low-overhead setup helps protect cash and speed decisions.
| Support activity | 2025 fact |
|---|---|
| Infrastructure | 3 marketed therapies |
| People | Lean cross-functional teams |
| Procurement | CROs, CMOs, API, packaging |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Mirum Pharmaceuticals runs inbound logistics through tightly controlled supplier and contract-manufacturing networks for APIs, excipients, and packaging materials. With a 3-product rare-disease portfolio in 2025, lot traceability and quality release matter more, because one missed shipment can affect patient supply fast. The setup supports uninterrupted flow, but it also raises reliance on a small supplier base and tight inventory control.
Operations
Operations at Mirum Pharmaceuticals cover clinical development, regulatory execution, quality oversight, pharmacovigilance, and outsourced manufacturing management, so trial data can move into approved medicines. In fiscal 2025, Mirum Pharmaceuticals had 2 marketed therapies, LIVMARLI and CTEXLI, and kept a focused pipeline aimed at rare liver diseases. This is the part of the chain that turns science into reimbursable products while keeping supply, safety, and compliance tight.
Outbound Logistics
Mirum Pharmaceuticals routes outbound logistics through specialty pharmacies, distribution partners, and market-access channels to reach patients with rare liver disease. This setup supports prior authorization, shipment tracking, and prescription fulfillment, which matters because these therapies are tightly controlled and must move quickly and accurately.
The model fits Mirum Pharmaceuticals' orphan-drug focus: smaller patient pools, more payer checks, and higher service needs than standard retail drugs.
Marketing and Sales
Marketing and Sales matters most for Mirum Pharmaceuticals because its rare-disease products depend on specialist prescribers, payer pull-through, and diagnosis support, not broad consumer ads. Mirum Pharmaceuticals had 2 rare-disease products with 3 approved uses in 2025, so field teams must educate physicians, speed referrals, and win reimbursement case by case. In this channel, one new diagnosis or prior-authorization win can matter more than wide reach.
Service
Service is a key value-chain step for Mirum because reimbursement support, patient onboarding, adherence follow-up, and safety monitoring keep rare-disease patients on therapy after launch. In rare disease, success often depends less on script volume and more on prior-authorization speed, dose management, and long-term persistence, since even small drop-offs can weaken outcomes and revenue.
Mirum Pharmaceuticals' Rare-Disease Growth Hinges on Every Prescription
Mirum Pharmaceuticals' primary activities in fiscal 2025 centered on moving 2 marketed therapies, LIVMARLI and CTEXLI, from specialist demand to patient use. Marketing and sales focused on rare-disease physicians and payer access, while service kept prior authorization, onboarding, adherence, and safety support tight. This model fits 3 approved uses and a small patient pool, where each filled prescription matters.
| Primary activity | 2025 fact |
|---|---|
| Marketing and sales | 2 marketed therapies |
| Service | 3 approved uses |
Preview the Actual Deliverable
Mirum Reference Sources
This is the actual Mirum Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is exactly what you'll get. Purchase unlocks the complete, detailed version of the same file.
Frequently Asked Questions
Mirum Pharmaceuticals' value chain is driven by rare-disease commercialization around 2 marketed therapies and 3 approved uses. Livmarli addresses Alagille syndrome and PFIC, while Ctexli targets adult CTX. That mix concentrates value in regulatory execution, specialty distribution, and patient support rather than large-scale manufacturing capacity.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.